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Abstract (Max 250) 
 
 
Alzheimer's disease (AD) is the main cause of dementia in the elderly population. 
Over 30 million people worldwide are living with dementia and AD prevalence is 
projected to increase dramatically in the next two decades. In terms of 
neuropathology, AD is characterized by two major cerebral hallmarks: extracellular 
β-amyloid (Aβ) plaques and intracellular tau inclusions, which start accumulating in 
the brain 15-20 years before the onset of symptoms. Within this context, the 
scientific community worldwide is undertaking a wide research effort to detect AD 
pathology at its earliest, before symptoms appear. Neuroimaging of Aβ by positron 
emission tomography (PET) is clinically available and used for AD diagnosis and 
staging of Aβ pathology. Substantive efforts are ongoing to develop advanced 
imaging techniques for early detection of tau pathology. Here, we will briefly 
describe the key features of tau pathology and its heterogeneity across various 
neurodegenerative diseases bearing cerebral tau inclusions (i.e., tauopathies). We 
will outline the current status of research on tau-specific PET tracers and their 
clinical development. Finally, we will discuss the potential application of novel super-
resolution and label-free techniques for investigating tau pathology at the 
experimental level and their potential application for AD diagnosis.  
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Alzheimer's disease (AD) is the main cause of dementia in the elderly population. It 
has been estimated that over 30 million people worldwide are living with dementia 
and AD prevalence is projected to increase dramatically in the next two decades 
(Hebert and others, 2013). In terms of neuropathology, AD is characterized by two 
major cerebral hallmarks: extracellular β-amyloid (Aβ) plaques and intracellular tau 
inclusions, which start accumulating in the brain 15-20 years before the onset of 
subtle clinical symptoms (Bateman and others, 2012). Within this context, the 
scientific community worldwide is undertaking a wide research effort to detect AD 
pathology at its earliest, before symptoms appear. This is of utmost importance 
given the consensus in the field that medical treatments should be administered at 
the earliest stages of the disease to maximize their efficacy in ameliorating or 
slowing down dementia symptoms.  
A variety of strategies are currently being tested to identify suitable disease 
biomarkers for early recognition of pathological hallmarks. Among those, one 
promising approach is the detection of neuropathological hallmarks by advanced 
imaging techniques.  
Molecular imaging of Aβ through positron emission tomography (PET) has 
successfully reached clinical stage with the approval of Aβ-specific PET tracers and is 
a promising modality for early detection of Aβ and AD diagnosis (reviewed in (Adlard 
and others, 2014)). In fact, a negative Aβ scan substantially decreases the odds of a 
person having AD and can impact clinical decision making or treatments. In at-risk 
patients, a positive scan is associated with a three-fold increase of the risk of 
converting to dementia (Doraiswamy and others, 2014). One main limitation of Aβ 
imaging by PET is that amyloid plaques by themselves are insufficient for a definite 
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diagnosis of AD. For this, detection of tau pathology would also be required, which 
explains the wide interest for developing imaging techniques for early its detection 
to aid clinical diagnosis. Here, we will briefly describe the key features of tau 
pathology and its heterogeneity across various neurodegenerative diseases bearing 
cerebral tau inclusions (i.e., tauopathies). We will outline the current status of 
research on tau-specific PET tracers and their clinical development. Finally, we will 
discuss the potential application of novel super-resolution and label-free techniques 
for investigating tau pathology at the experimental level and their potential 
application for AD diagnosis.  
Tau histopathology 
In 1988, seminal studies by Goedert, Wischik and colleagues (Goedert and others, 
1988; Wischik and others, 1988a; Wischik and others, 1988b) demonstrated that the 
microtubule-associated protein tau is the structural component of paired helical 
filaments (PHF), which are the building blocks of the intracellular tau inclusions first 
described in the brain of AD patients. Since then, extensive neuropathological 
evidence has shown the presence of deposits of tau in a variety of 
neurodegenerative diseases termed tauopathies, including frontotemporal lobe 
dementia, Pick’s disease, corticobasal degeneration and parasupranuclear palsy. This 
phenomenon was initially thought to be a non-specific event accompanying the 
neurodegenerative process.  However, the identification of mutations in the 
tau gene causative of FTDP-17 has demonstrated that tau and its aggregation have a 
key role in neurodegeneration and neuronal death (reviewed in (Gasparini and 
others, 2007).  
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Tau inclusions manifest with variously shaped deposits that develop both in neurons 
and glia with distinctive features across tauopathies. The main structures of 
Alzheimer-type tau pathology are the so-called neurofibrillary tangles (NFTs). NFTs 
are flame-shaped or globose intraneuronal inclusions stained by silver and affecting 
neuron perykaria and proximal neurites. Tau deposits also form in distal isolated 
dendrites (neuropil threads) and in clustered dystrophic neurites (neuritic plaques). 
NFTs are composed of protein filaments of various structures, including PHF (Kidd, 
1963; 1964) and straight filaments (SF). Both PHF and SF from AD are made of 
abnormally phosphorylated tau protein (Bramblett and others, 1993; Goedert and 
others, 1992). Tau inclusions have also been shown in glial cells. Coiled bodies and 
glial threads are inclusions typical of oligodendroglia and they are predominantly 
found in white matter. Characteristic tau deposits can be found also in astrocytes in 
the shape of thorned and tuft astrocytes and astrocytic plaques.  
Tau pathology progression and spreading 
As for Aβ, tau pathology starts to develop many years before clinical symptoms 
(Bateman and others, 2012). The formation of tau inclusions progresses with a 
typical anatomical pattern as demonstrated by the seminal neuropathological work 
of Braak and Braak (1997) that provide the framework for disease severity staging in 
AD. In presymptomatic stages of the disease (Stage I and II), tau inclusions appear in 
the entorhinal cortex and hippocampus. During stage III and IV, tau pathology 
spreads to the occipito-temporal and insular cortices. At this disease stage, only 
subtle subclinical manifestations occur. In the following stage V-VI, tau inclusions 
spread throughout the entire cortex (Braak and Braak, 1997). When tau pathology 
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reached these final stages, AD is fully symptomatic and a definite diagnosis of 
dementia can be made. 
Recent findings indicate that tau pathology spreads in a hierarchical manner among 
anatomically connected areas (Ahmed and others, 2014; de Calignon and others, 
2012; Hyman, 2014). According to the prion-hypothesis, aggregated forms of tau 
transfer from one cell to the other in vitro (Frost and others, 2009a). In fact, tau 
aggregates are released from the cells of origin and are taken up by neighboring 
cells, where they seed further filament formation (Frost and Diamond, 2010). 
Further, recombinant tau fibrils induce aggregation of intracellular full-length tau in 
cultured cells (Kfoury and others, 2012). In vivo, injection of brain lysate from the 
P301S tau transgenic model of tauopathy into the brains of mice expressing wild 
type human tau induces assembly of wild type tau into filaments and spreading of 
tau pathology across the brain (Clavaguera and others, 2013; Mazzaro and others, 
2016). Similar results were obtained with injection of filaments of recombinant 
human tau, which cause rapid induction of tau inclusions in the site of injection and 
subsequent propagation of tau pathology to interconnected areas (Iba and others, 
2013). Such propagation of tau aggregates throughout the brain does not require 
the presence of endogenous Tau in the recipient neurons (Wegmann and other, 
2015) but is helped by microglia (Asai and others, 2015). The mechanisms underlying 
the spreading behavior of tau aggregates are still poorly understood. It has been 
proposed that tau spreading may occur through trans-synaptic movement of tau 
aggregates (de Calignon and others, 2012). However, the cell endocytic pathway 
appears also involved in the process of tau aggregation and pathology propagation. 
In fact, recent studies with super resolution microscopy have uncovered a previously 
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unrecognized role for extracellular monomeric tau in the transcellular spreading of 
tau aggregates (Michel and others, 2014). 
PET imaging of tau: a promise for the future 
Following the successful clinical application of PET imaging for Aβ, substantive 
efforts are ongoing to develop PET tracers for detecting tau inclusions.  However, the 
peculiar features of tau inclusions pose several hurdles. First of all, tracer specificity 
and selectivity should take into account two main factors: i) tau inclusions vary in 
structure (both macro and ultrastructure), post-translational modifications (e.g., 
phosphorylation, glycation), and location (intra-neuronal vs intra-glial) across 
different tauopathies; ii) the amount of tau pathology is significantly lower than that 
of Aβ pathology (Mukaetova-Ladinska and others, 1993; Naslund and others, 2000); 
and iii) potential binding to protein aggregates occurring in other neurodegenerative 
diseases may give false positive results. The resolution of these aspects is obviously 
fundamental to discriminate different neuropathological hallmarks and therefore, 
different diseases. Second, affinity for the target structure would also contribute to 
define the specificity and selectivity of PET tracers against tau. Last, biophysical 
properties, pharmacokinetics and safety matters should be addressed to get optimal 
entry in the brain and distribution of the tracer in a safe manner. Despite all these 
difficulties, several molecules have been developed in recent years with enhanced 
tau binding capabilities and limited or no Aβ detection (reviewed in (Villemagne and 
others, 2015). Such compounds are still in research/early development stage and will 
undergo extensive investigation and validation to enter the clinical use in the near 
future. 
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Imaging tau pathology: experimental and clinical application of super-resolution 
microscopy 
The advent of optical super-resolution microscopy techniques has led to a paradigm 
shift in the field of protein misfolding diseases: Using the technique of direct 
Stochastic Optical Reconstruction Microscopy, dSTORM (Heilemann and others, 
2008), it has been possible to image in vitro and in cells the morphology of Aβ fibrils 
with a resolution better than 20 nm (Kaminski Schierle and others, 2011). The 
technique thus affords a spatial resolution approaching that of atomic force 
microscopy (AFM) or scanning electron microscopy (SEM) techniques, whilst offering 
the advantages of specificity and sensitivity that come with all-optical techniques.  
Using single-molecule localisation microscopy (SMLM) the presence of 
polyglutamine aggregates within cells has been demonstrated with molecular 
resolution (Sahl and others, 2012). In the latter, fibrillary polyglutamine species 
formed in cells displayed a number of structural similarities to those observed in 
vitro (Duim and others, 2011), which is different to observations made for Aβ using a 
similar approach (Kaminski Schierle and others, 2011). Moreover, aggregation of 
human lysozyme, which occurs in case of hereditary amyloidosis linked to specific 
lysozyme mutations, were observed both in vitro and in cells using dSTORM and 
showed similar morphological features (Ahn and others, 2012). 
These studies led the way to further investigations, such as measurements of 
amyloid growth (polymerization) using multi-color SMLM approaches as applied to 
α-synuclein (Pinotsi and others, 2014; Pinotsi and others, 2016; Roberti and others, 
2012) or polyglutamine (Duim and others, 2014). Further, two-color SMLM was used 
to reveal potential mechanisms of propagation of Tau protein by showing the 
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association of extracellular and endogenous Tau proteins, which are released 
together into the extracellular medium (Michel and others, 2014). The latter finding 
highlights the risk associated with increased levels of extracellular Tau, which in AD 
patients may drive the spreading of tau pathology. Furthermore, another SMLM-
based study demonstrated that in cells, the kinetics of aggregation of mutant Aβ is 
faster than wild type Aβ, revealing the pathological role of mutant Aβ in AD 
(Esbjorner and others, 2014). Similarly, two-color SMLM was used to observe that Aβ 
obtained from the soluble fraction of brain extracts of AD patients showed higher 
seeding capabilities than that extracted from cerebrospinal fluid (Fritschi and others, 
2014). The latter study has been the first implementation of super-resolution 
microscopy toward AD diagnostic: such technique may be valuable for the early 
onset detection of Tau pathology since in contrast to Aβ, Tau levels in the CSF 
increase as the disease progresses (Tapiola and others, 2009). A potential ex vivo 
diagnostic paradigm based on these results with super-resolution imaging is outlined 
in Figure 1. 
Thus far, SMLM techniques have demonstrated an invaluable potential for the study 
of neurodegenerative diseases, with its molecular resolution and specificity. 
However, numerous questions remain unanswered, such as, what is the interaction 
of each amyloid species with the cellular machinery? Which species are responsible 
for the triggering of cell death? What is the effect of the presence of these fibrillar 
structures on synaptic transmission? Super-resolution fluorescence techniques are 
capable to lift the cover on the molecular interactions of these pathologies and thus 
may pave the way for novel diagnostic assays and therapeutic strategies to prevent 
these devastating diseases. 
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Future perspective of label-free imaging of tau pathology imaging  
The imaging of tau inclusions in experimental and neuropathological procedures 
strongly relies on the use of immunohistochemistry and immunofluorescence using a 
combination of tau-specific antibodies and dyes recognizing the typical cross-β-sheet 
structure of tau filaments, such as Thioflavin S, Congo red and derivatives like FSB 
(Figure 2). This approach is informative on the content of tau protein, its post-
translational modification (e.g. phosphorylation) and to some extent, cross-β-sheet 
content of inclusions. However, the differential amount of tau filaments in soma and 
neurites (the amount in neuritis is extremely low compared to soma – see Figure 2) 
poses significant challenges to the concomitant imaging of these compartments. 
Further, current techniques cannot provide information of the dynamics of tau 
aggregation, nor on the type of aggregate strains contained in the inclusions. The 
application of label-free spectroscopic principles to the microscopy field will possibly 
further innovate the imaging of tau pathology in the future. Efforts to apply Raman, 
infrared (IR) spectroscopy and intrinsic amyloid fluorescence principles are ongoing. 
Implementing such techniques would add significant information about the 
chemistry of the sample and/or the presence of specific structural features (e.g., β-
sheet conformation of aggregates) and their dynamic structural changes in time. 
Neither Raman, IR nor intrinsic amyloid fluorescence microscopy has been currently 
applied to image tau inclusions. However, spectroscopic studies of recombinant tau 
aggregates provide hints on the potential information we might get from the 
development of such techniques. Fourier transform IR (FT-IR) spectroscopy has been 
applied to detect the content of α-helices and cross-β-sheet structure in filaments 
obtained by the aggregation in vitro of human recombinant tau protein or tau 
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filaments extracted from AD brain samples (Berriman and others, 2003; Sadqi and 
others, 2002; Schweers and others, 1994). Through FT-IR, it has been also possible to 
monitor the transition from random-coil to β-sheet structure during the aggregation 
of recombinant human tau in vitro. The spectra obtained by FT-IR spectroscopy show 
a maximum at 1650 cm
-1
 for the soluble, unfolded tau protein and a shoulder at 
1630 cm
-1
 only in samples of aggregated tau protein (von Bergen and others, 2005). 
Importantly, such a shoulder is also detected in PHF extracted from samples of AD 
brain (von Bergen and others, 2005) and is consistent with the presence of β-sheet 
structure in such filaments (Berriman and others, 2003). FT-IR also detects β-sheet 
content in tau filaments with diverse conformation (Frost and others, 2009b). 
Likewise, UV Raman Resonance (UVRR) spectroscopy has been applied to investigate 
the aggregation of recombinant tau in vitro, yielding interesting results on the 
complexity of the dynamic of tau aggregation (Ramachandran and others, 2014). 
These results indicate that this technique is potentially applicable to the analysis of 
the variety of tau aggregates conformations associated with different tau lesions. 
The use of FT-IR spectroscopy principles in combination with probes specific for tau 
may allow to selectively image tau pathology combining spatial, chemical and 
conformational details. Within this context, it is noteworthy to mention the 
possibility to use tau specific antibody fragments labeled with fluorescent near-IR 
dyes (Krishnaswamy and others, 2014) and efforts to develop pathology-specific 
probes for near-infrared imaging, such as those developed for Aβ pathology 
(Schmidt and Pahnke, 2012).  
Furthermore, intrinsic fluorescence of amyloids has been applied to study α-
synuclein fibril growth in a label-free manner in vitro (Pinotsi and others, 2013). 
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Similar intrinsic fluorescence can be observed in fibrils formed by different variants 
of recombinant Tau (Figure 3) (Chan and others, 2013; Chan and others, 2014; 
Michel and others, 2014). The latter has further been successfully applied to develop 
an amyloid sensor for the study of amyloid aggregation in live cells (Esbjorner and 
others, 2014; Kaminski and others, 2014; Kaminski Schierle and others, 2011; 
Kaminski Schierle and others, 2014; Kumar and others, 2014; Michel and others, 
2014). Whether or not the intrinsic amyloid fluorescence is amendable to super-
resolution microscopy is currently under investigation. One foreseeable problem is 
discriminating tau intrinsic fluorescence from background fluorescence within tissue.  
In conclusion, the development of super resolution microscopy is revolutionizing the 
imaging paradigms providing unprecedented tools for investigating the 
pathophysiological mechanisms of AD driven by aggregation of pathological 
proteins, such as Aβ and tau. The future development of label-free high resolution 
techniques will further advance our capabilities adding structural information to the 
qualitative specificity of optical imaging. 
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Figures and legends 
 
Figure 1 – Ex-vivo Screening test for patients with neurodegenerative diseases 
applying super-resolution microscopy. Patients could be screened for Alzheimer’s 
disease, or other amyloid-caused neurodegenerative disease, with the use of CSF 
samples. Each patient sample could be divided into fractions, each incubated with an 
excess amount of labelled monomer of amyloid proteins such as Aβ, Tau, α-
synuclein, huntingtin. The presence of seeds in the CSF sample would then be 
probed by super-resolution imaging of monomer elongation, the frequency of 
elongated fibrils being correlated with the number of seeds present in the patient’s 
CSF and therefore the stage of the disease. 
Figure 2 - Representative maximal projection of confocal z-stack images of one 
retinal ganglion neuron from the P301S mutant human tau transgenic mouse model 
of tauopathy (Allen and others, 2002) bearing inclusions of phosphorylated tau 
filaments containing β-sheet secondary structure. Phosphorylated tau (b; c, green) 
was visualized by immunostaining with AT8 anti-phospho-tau monoclonal antibodies 
and aggregates with β-sheet conformation were counterstained using the Congo red 
analogue FSB (a; c, blue) as previously described (Gasparini and others, 2011). Arrow 
and arrowheads indicate FSB
+
/AT8
+
 aggregates in soma and dendrites, respectively. 
Panels d-f images corresponding to squared areas 1 (d), 2 (e) and 3 (f) in a-b 
representing FSB staining (i panels) and AT8 immunoreactivity (ii panels). Scale bars: 
25 μm. 
Figure 3 – Tau fibrils display intrinsic fluorescence in the visible range. A: 10 µM 
recombinant K18Tau protein fragment, which contains the four repeat domain of full 
Page 17 of 21 Microscopy Research and Technique
 18
length human Tau (Barghorn and Mandelkow, 2002), was incubated with 10 µM 
heparin 5000 MW (Fisher Scientific, Loughborough, UK) for 2 days at 37°C in 
phosphate buffer saline. Fibrils formed were imaged on a Nikon TE inverted 
microscope with a 100x, 1.49 NA TIRK objective and a 405 nm excitation laser source 
(Mitsubishi Electronics Corp., Tokyo, Japan).  The fluorescence light in the detection 
path was filtered by a dichroic filter (Semrock multi-edge dichroic Di01-
R405/488/561/635-25x36 followed by a FF01-446/523/600/677-25 filter, Semrock, 
Rochester NY, USA) and was subsequently filtered further using an additional 452/45 
band-pass filter (Semrock), before being projected onto an electron-multiplying CCD 
camera (Andor ixon 887DV, Belfast, Northern Ireland). i) White light image of a 
cluster of Tau fibrils, ii) Overlay between the white light and fluorescence image and 
iii) Fluorescence image only. B: Emission spectrum of K18Tau fibrils, measured at 
25°C using a TCS SP5 Leica confocal microscope (Leica Microsystems UK Ltd., Milton 
Keynes, UK). Note, monomeric K18Tau does not display any detectable fluorescence. 
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Figure 1 – Ex-vivo Screening test for patients with neurodegenerative diseases applying super-resolution 
microscopy. Patients could be screened for Alzheimer’s disease, or other amyloid-caused neurodegenerative 
disease, with the use of CSF samples. Each patient sample could be divided into fractions, each incubated 
with an excess amount of labelled monomer of amyloid proteins such as Aβ, Tau, α-synuclein, huntingtin. 
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Figure 2 - Representative maximal projection of confocal z-stack images of one retinal ganglion neuron from 
the P301S mutant human tau transgenic mouse model of tauopathy (Allen and others, 2002) bearing 
inclusions of phosphorylated tau filaments containing β-sheet secondary structure. Phosphorylated tau (b; c, 
green) was visualized by immunostaining with AT8 anti-phospho-tau monoclonal antibodies and aggregates 
with β-sheet conformation were counterstained using the Congo red analogue FSB (a; c, blue) as previously 
described (Gasparini and others, 2011). Arrow and arrowheads indicate FSB+/AT8+ aggregates in soma and 
dendrites, respectively. Panels d-f images corresponding to squared areas 1 (d), 2 (e) and 3 (f) in a-b 
representing FSB staining (i panels) and AT8 immunoreactivity (ii panels). Scale bars: 25 µm.  
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Figure 3 – Tau fibrils display intrinsic fluorescence in the visible range. A: 10 µM recombinant K18Tau 
protein fragment, which contains the four repeat domain of full length human Tau (Barghorn and 
Mandelkow, 2002), was incubated with 10 µM heparin 5000 MW (Fisher Scientific, Loughborough, UK) for 2 
days at 37°C in phosphate buffer saline. Fibrils formed were imaged on a Nikon TE inverted microscope with 
a 100x, 1.49 NA TIRK objective and a 405 nm excitation laser source (Mitsubishi Electronics Corp., Tokyo, 
Japan).  The fluorescence light in the detection path was filtered by a dichroic filter (Semrock multi-edge 
dichroic Di01-R405/488/561/635-25x36 followed by a FF01-446/523/600/677-25 filter, Semrock, Rochester 
NY, USA) and was subsequently filtered further using an additional 452/45 band-pass filter (Semrock), 
before being projected onto an electron-multiplying CCD camera (Andor ixon 887DV, Belfast, Northern 
Ireland). i) White light image of a cluster of Tau fibrils, ii) Overlay between the white light and fluorescence 
image and iii) Fluorescence image only. B: Emission spectrum of K18Tau fibrils, measured at 25°C using a 
TCS SP5 Leica confocal microscope (Leica Microsystems UK Ltd., Milton Keynes, UK). Note, monomeric 
K18Tau does not display any detectable fluorescence.  
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